article thumbnail

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

Pharmaceutical Technology

CB1 is predominantly found in the central and peripheral nervous system, whereas CB2 is primarily located in immune cells. Currently, Jazz Pharmaceuticals’s nabiximols is the only cannabinoid approved for pain, receiving approval in Israel, in August 2010.

Immunity 143
article thumbnail

New cancer vaccine method boosts potency and scope

World Pharma News

Vaccines to treat cancers have been around since 2010, the first being approved for prostate cancer, and another in 2015 for melanoma. One hurdle is the difficulty in finding antigens in tumors that look foreign enough to trigger an immune response.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

BREAKING NEWS: Moderna sues Pfizer and BioNTech over mRNA COVID-19 vaccines

European Pharmaceutical Review

Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology.

article thumbnail

Queen’s Award for Enterprise goes to SGS’s Quay Pharma

European Pharmaceutical Review

The Queen’s Award for Enterprise is the UK’s highest accolade for business success and recognises the strength of Quay Pharma’s export sales, which, according to SGS, have comprised at least 55 percent of its business since 2010. The enterprise also noted that in the last three years its overseas sales had more than doubled.

article thumbnail

NICE rejects Orchard’s gene therapy for rare childhood disease MLD

pharmaphorum

Libmeldy originated from a collaboration between GlaxoSmithKline and Fondazione Telethon and Ospedale San Raffaele, acting through their joint San Raffaele-Telethon Institute for Gene Therapy in Milan, initiated in 2010.

article thumbnail

WHO prequalifies meningitis conjugate vaccine

European Pharmaceutical Review

This news builds on the success of the MenAfriVac ® vaccine, which eliminated serogroup A meningococcal meningitis outbreaks from the meningitis belt after being introduced in 2010. “[We] They do not promote herd immunity and are not generally effective in infants and children younger than two years old.

article thumbnail

mRNA researchers awarded 2023 Nobel Prize

European Pharmaceutical Review

The discoveries by the two Nobel Laureates have revolutionised science’s understanding of how messenger RNA (mRNA) interacts with the immune system. In 2010, several companies were working on developing the method. The discovery was critical for developing effective mRNA vaccines during the COVID-19 pandemic.

Vaccines 111